The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial.
about
Advances in rheumatology: new targeted therapeuticsCertolizumab pegolBiologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritisRisk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studiesSubcutaneous abatacept for the treatment of rheumatoid arthritis.New pharmacological strategies in rheumatic diseasesLong-term safety of subcutaneous abatacept in rheumatoid arthritis: integrated analysis of clinical trial data representing more than four years of treatment.Retention of the second-line biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis failing one tumor necrosis factor alpha inhibitor: data from the BioRx.si registry.Restoring the balance: immunotherapeutic combinations for autoimmune diseaseRisk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted BiologicsRationale of using different biological therapies in rheumatoid arthritis.Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study.The efficacy of biologic agents in patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor inhibitors: a systematic review.Abatacept treatment for rheumatoid arthritisClinical efficacy of abatacept compared to adalimumab and tocilizumab in rheumatoid arthritis patients with high disease activity.Choice of Biologic Therapy for Patients with Rheumatoid Arthritis: The Infection Perspective.Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study.Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-α inhibitorsEmerging drugs for the treatment of ulcerative colitisThe efficacy and safety of abatacept in rheumatoid arthritis.Usability and Acceptability of the Abatacept Pre-Filled Autoinjector for the Subcutaneous Treatment of Rheumatoid Arthritis.The clinical efficacy and safety of certolizumab pegol (CZP) in the treatment of rheumatoid arthritis: focus on long-term use, patient considerations and the impact on quality of lifeNew and emerging therapies for the treatment of rheumatoid arthritis.Non-tumor necrosis factor-based biologic therapies for rheumatoid arthritis: present, future, and insights into pathogenesis.Patient-Reported Outcomes From a Two-Year Head-to-Head Comparison of Subcutaneous Abatacept and Adalimumab for Rheumatoid Arthritis.A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview.Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study.A critical evaluation of the role of subcutaneous abatacept in the treatment of rheumatoid arthritis: patient considerations.ACR70-disease activity score remission achievement from switches between all the available biological agents in rheumatoid arthritis: a systematic review of the literature.Description of the efficacy and safety of three new biologics in the treatment of rheumatoid arthritis.The clinical efficacy and safety of certolizumab pegol in rheumatoid arthritis.The efficacy and safety of golimumab in the treatment of arthritis.The risk of tuberculosis in patients treated with TNF antagonists.Safety of biologic therapy in rheumatoid arthritis.Gene therapy for rheumatoid arthritis: current status and future prospects.Optimizing outcomes in patients with rheumatoid arthritis and an inadequate response to anti-TNF treatment.When is switching warranted among biologic therapies in rheumatoid arthritis?Abatacept: a review of its use in the management of rheumatoid arthritis.Update on the use of abatacept for the treatment of rheumatoid arthritis.Comparative clinical utility of once-weekly subcutaneous abatacept in the management of rheumatoid arthritis.
P2860
Q21093257-45DF0BD5-1A15-4F9E-9BB2-6109CC4F7439Q24625401-1EB23E16-63DB-4B6B-9239-22EF286205AAQ26852235-F40AC5DB-EE47-4E31-9B47-186D51FEE6B2Q26991673-8B7303DC-936F-4C50-83EA-5A996BEA00E7Q27692117-FCE29DF2-D961-4BDB-AB4B-950B9A209BC7Q28073763-15F4CA3A-FF0D-4C15-94B5-A9ED6CD1A13BQ30811550-B7EFA01F-1760-4E55-97B9-FBF61FF005CBQ30991911-D2AD6C64-BD15-4CCE-9245-6D138BE44938Q33555986-17623A1D-4769-4DC5-BDBF-7C38A18576B7Q33809045-D4CEF8F9-47CC-49E8-B406-81F51EEE2CF2Q34153073-CBE5E5F9-0652-4769-9BD6-D7A72EB022C4Q34237578-B15DB91E-3012-474B-A3D1-FABF1EE238CDQ34401527-046CEB2A-FF3B-4536-AB85-CB971914F95EQ34588972-57FD9336-EC94-45CC-BFCB-90C999FDFD19Q34656204-971A1B55-4F33-4E93-9369-AACDC02AAF77Q35237588-A8B2114D-58B4-4713-9429-78E55BBA0FF3Q35249636-9B6878CC-E395-4671-B14E-BDCB7175EC80Q35620336-5EA466EA-3A9E-44D5-A1F1-BAEE83259B0AQ36039436-CF2D4AFC-E1D2-48F5-8EFE-AB6D531493A0Q36059373-865676CB-0872-4BA9-8F78-8652A4913A9EQ36626213-8755E1EC-523C-443F-998F-D033FFFFC005Q37358093-47E344D4-03F2-40AC-994D-DA7F121B4835Q37358229-9550946A-7088-4A8C-A645-CB33D465505AQ37388213-2632492B-E610-4F68-9F39-E39C54BADA0EQ37391811-9167959F-9749-41BF-AA91-6A20830AD56BQ37428436-F006D50B-F2A5-45E4-BAE2-954B7E90F240Q37501529-B306D22A-E51C-4AEA-B0E5-109AA67D922CQ37600477-601BBAEB-1BE8-4852-A31E-483BF78EBFCDQ37626889-35D579A1-D3BA-4566-88A9-C27BBD76E468Q37701273-5205CBA4-99A4-4916-9E19-88C45B75C591Q37709364-34C1DE2E-B50E-4C9B-B099-28C908B95033Q37760938-FA405BA3-49B0-4504-9C9F-7096B04AE16BQ37877262-E62197B5-6815-4C64-A45A-EFDD901BC1BEQ37944433-1686CC79-782C-494B-A238-9DBD87C151DDQ37952287-9C189E04-F5F2-4E28-997A-124FEA6152C8Q38020460-ED98ED2E-C860-4F3A-89B6-0FBE546F406EQ38027571-7A8DAB6E-2F66-4E0D-8ADE-44EE3B57718FQ38116472-82BEA4AD-E2BB-4492-8C08-3FC1AEDD9A24Q38125240-4540423C-18D2-4E48-8877-2CDE0F3B9FD2Q38210539-2C4570AA-2B22-4A76-8824-248AF4E34809
P2860
The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The 6-month safety and efficac ...... o abatacept: the ARRIVE trial.
@en
The 6-month safety and efficac ...... o abatacept: the ARRIVE trial.
@nl
type
label
The 6-month safety and efficac ...... o abatacept: the ARRIVE trial.
@en
The 6-month safety and efficac ...... o abatacept: the ARRIVE trial.
@nl
prefLabel
The 6-month safety and efficac ...... o abatacept: the ARRIVE trial.
@en
The 6-month safety and efficac ...... o abatacept: the ARRIVE trial.
@nl
P2093
P2860
P356
P1476
The 6-month safety and efficac ...... o abatacept: the ARRIVE trial.
@en
P2093
C Pritchard
J E Huffstutter
M C Genovese
V Rodriguez-Valverde
P2860
P304
P356
10.1136/ARD.2008.099218
P407
P577
2008-12-15T00:00:00Z